| scholarly article | Q13442814 |
| P50 | author | Alfred Ayala | Q55314071 |
| Richard S Hotchkiss | Q90459818 | ||
| P2093 | author name string | Jacqueline Unsinger | |
| Noelle A Hutchins | |||
| P2860 | cites work | Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency | Q22008480 |
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Molecular mechanisms of T cell co-stimulation and co-inhibition | Q26864888 | ||
| Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques | Q27346577 | ||
| Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care | Q27860820 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution | Q28251498 | ||
| BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 | Q28589743 | ||
| The epidemiology of sepsis in the United States from 1979 through 2000 | Q29547760 | ||
| PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 | ||
| The pathophysiology and treatment of sepsis | Q29619103 | ||
| Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy | Q33597681 | ||
| Interleukin-7 regulates Bim proapoptotic activity in peripheral T-cell survival | Q33614042 | ||
| Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. | Q33638464 | ||
| B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients | Q33753374 | ||
| Clinical aspects: from systemic inflammation to 'immunoparalysis'. | Q33801971 | ||
| Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy | Q33828888 | ||
| Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza | Q33875118 | ||
| PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine | Q33950150 | ||
| Deficiency of Bid protein reduces sepsis-induced apoptosis and inflammation, while improving septic survival | Q34017334 | ||
| IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. | Q34039180 | ||
| IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. | Q34120958 | ||
| IL-7 in human health and disease | Q34260682 | ||
| Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model | Q34420239 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis | Q34605998 | ||
| Sepsis definitions: time for change | Q34649118 | ||
| Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines | Q34657707 | ||
| Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques | Q35001598 | ||
| Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways | Q35070674 | ||
| Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. | Q35559497 | ||
| PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction | Q35561405 | ||
| Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients | Q35567048 | ||
| In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice | Q35848213 | ||
| Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. | Q35874111 | ||
| Immunosuppression in patients who die of sepsis and multiple organ failure | Q35991015 | ||
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study | Q36053935 | ||
| The late phase of sepsis is characterized by an increased microbiological burden and death rate | Q36070469 | ||
| The dual functions of receptor interacting protein 1 in fas-induced hepatocyte death during sepsis | Q36394948 | ||
| Role of IL-15 in Sepsis-Induced Skeletal Muscle Atrophy and Proteolysis | Q36512051 | ||
| B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells. | Q36729527 | ||
| Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets | Q36742299 | ||
| Prevention of lymphocyte cell death in sepsis improves survival in mice | Q36748242 | ||
| PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis | Q36750008 | ||
| Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. | Q36941194 | ||
| Regulatory T cell populations in sepsis and trauma. | Q36959555 | ||
| Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis | Q36997987 | ||
| Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach | Q37233354 | ||
| Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. | Q37238322 | ||
| The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients | Q37309561 | ||
| PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. | Q37351521 | ||
| Cytomegalovirus reactivation in critically ill immunocompetent patients | Q37414600 | ||
| Endotoxin tolerance: new mechanisms, molecules and clinical significance | Q37603612 | ||
| Sepsis-induced potentiation of peritoneal macrophage migration is mitigated by programmed cell death receptor-1 gene deficiency. | Q37678563 | ||
| Neutrophil paralysis in sepsis | Q37780438 | ||
| Harnessing the biology of IL-7 for therapeutic application | Q37867487 | ||
| Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival | Q37989867 | ||
| The function of neutrophils in sepsis | Q37994057 | ||
| Interleukin-15 in gene therapy of cancer. | Q38060229 | ||
| B7 family checkpoint regulators in immune regulation and disease | Q38129635 | ||
| Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial | Q38316900 | ||
| Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. | Q38483410 | ||
| Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria | Q39855993 | ||
| Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. | Q40684512 | ||
| Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome | Q41155671 | ||
| Kupffer cells protect liver sinusoidal endothelial cells from Fas-dependent apoptosis in sepsis by down-regulating gp130. | Q41663817 | ||
| BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction | Q41897433 | ||
| Dose-dependent effect of anti-CTLA-4 on survival in sepsis | Q41976084 | ||
| The sepsis seesaw: tilting toward immunosuppression | Q42035078 | ||
| Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis | Q42229245 | ||
| Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway | Q43064735 | ||
| Decreased T-cell repertoire diversity in sepsis: a preliminary study | Q43514997 | ||
| Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated k | Q44234592 | ||
| Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity | Q44569265 | ||
| Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte | Q45018156 | ||
| Benchmarking the incidence and mortality of severe sepsis in the United States | Q45240119 | ||
| Virus detection in patients with severe pneumonia: still more questions than answers? | Q45355493 | ||
| TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy | Q46421735 | ||
| Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice | Q48648759 | ||
| Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. | Q52909875 | ||
| Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients | Q56906281 | ||
| Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction | Q57773627 | ||
| IL-7 Restores Lymphocyte Functions in Septic Patients | Q60547571 | ||
| Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock | Q60547604 | ||
| p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group | Q73343490 | ||
| Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans | Q73896312 | ||
| Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients | Q77754550 | ||
| Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice | Q77788085 | ||
| Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis | Q77855901 | ||
| Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis | Q78109886 | ||
| Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways | Q81621957 | ||
| Sepsis: calming the cytokine storm | Q84135047 | ||
| Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis | Q84255932 | ||
| P433 | issue | 4 | |
| P921 | main subject | sepsis | Q183134 |
| P304 | page(s) | 224-233 | |
| P577 | publication date | 2014-01-30 | |
| P1433 | published in | Trends in Molecular Medicine | Q15265842 |
| P1476 | title | The new normal: immunomodulatory agents against sepsis immune suppression | |
| P478 | volume | 20 |
| Q49375374 | A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. |
| Q64258136 | A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation |
| Q40075675 | Activated Mesenchymal Stem Cells Interact with Antibiotics and Host Innate Immune Responses to Control Chronic Bacterial Infections. |
| Q26783097 | Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis |
| Q47310265 | Advances in the understanding and treatment of sepsis-induced immunosuppression. |
| Q91260456 | Alpha-hemolysin of uropathogenic Escherichia coli induces GM-CSF-mediated acute kidney injury |
| Q40404109 | Anti-PD-L1 peptide improves survival in sepsis |
| Q38801190 | Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study |
| Q39693010 | Attrition of memory CD8 T cells during sepsis requires LFA-1 |
| Q47990314 | Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis. |
| Q64071561 | Brevenal, a Marine Natural Product, is Anti-Inflammatory and an Immunomodulator of Macrophage and Lung Epithelial Cells |
| Q36197106 | Chronic Alcohol Ingestion Delays T Cell Activation and Effector Function in Sepsis |
| Q37649004 | Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity |
| Q47192644 | Clinical implications of the plasma EphA2 receptor level in critically ill patients with septic shock |
| Q89939742 | Combination of Glutamine and Ulinastatin Treatments Greatly Improves Sepsis Outcomes |
| Q40989836 | Contribution of programmed cell death receptor (PD)-1 to Kupffer cell dysfunction in murine polymicrobial sepsis |
| Q36852546 | Could Biomarkers Direct Therapy for the Septic Patient? |
| Q90828848 | Current gaps in sepsis immunology: new opportunities for translational research |
| Q100395048 | Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study |
| Q41197887 | Desperate Times Call for Desperate Measures: Self-Cannibalism Is Protective During Sepsis |
| Q35153451 | Developing a clinically feasible personalized medicine approach to pediatric septic shock |
| Q92158624 | Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit |
| Q36259440 | Differential alterations of tissue T-cell subsets after sepsis. |
| Q35928330 | Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. |
| Q91057942 | Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology |
| Q41167339 | Effects of enteral nutrition with parenteral glutamine supplementation on the immunological function in septic rats |
| Q38929971 | Emerging infection and sepsis biomarkers: will they change current therapies? |
| Q30300333 | Emerging therapeutic targets of sepsis-associated acute kidney injury |
| Q38477939 | Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. |
| Q40526734 | Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. |
| Q36764754 | Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study |
| Q40116451 | High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. |
| Q90001240 | IL-10 Has Differential Effects on the Innate and Adaptive Immune Systems of Septic Patients |
| Q40400275 | IL-7 and procalcitonin are useful biomarkers in the comprehensive evaluation of the severity of acute cholangitis |
| Q60313561 | Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients |
| Q47219343 | Immune Function in Critically Ill Dogs. |
| Q40049630 | Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent |
| Q39066825 | Improved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates |
| Q38759043 | In vivo application of Granulocyte-Macrophage Colony-stimulating Factor enhances postoperative qualitative monocytic function |
| Q52579155 | Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy. |
| Q41609318 | Interleukin 4 Deficiency Reverses Development of Secondary Pseudomonas aeruginosa Pneumonia During Sepsis-Associated Immunosuppression |
| Q40539825 | Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia |
| Q35177535 | Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression |
| Q47331514 | Intracellular S100A9 Promotes Myeloid-Derived Suppressor Cells during Late Sepsis. |
| Q64250313 | LDK378 improves micro- and macro-circulation via alleviating STING-mediated inflammatory injury in a Sepsis rat model induced by Cecal ligation and puncture |
| Q92644931 | Long non-coding RNA PlncRNA-1 regulates cell proliferation, apoptosis, and autophagy in septic acute kidney injury by regulating BCL2 |
| Q57221538 | Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes |
| Q35562860 | Murine lung cancer induces generalized T-cell exhaustion |
| Q40342586 | Myeloid Cell-Specific Knockout of NFI-A Improves Sepsis Survival |
| Q36356983 | NFI-A disrupts myeloid cell differentiation and maturation in septic mice |
| Q39008991 | Neutrophil derived microparticles increase mortality and the counter-inflammatory response in a murine model of sepsis |
| Q90703154 | Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis |
| Q47102338 | Potential Immunotherapeutics for Immunosuppression in Sepsis |
| Q57160595 | Precision Immunotherapy for Sepsis |
| Q92736905 | Precision Medicine and its Role in the Treatment of Sepsis: A Personalised View |
| Q37728979 | Pro-Resolving Molecules-New Approaches to Treat Sepsis? |
| Q29994668 | Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
| Q36437648 | Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology. |
| Q55244233 | Pterostilbene attenuates acute kidney injury in septic mice. |
| Q34662282 | Revisiting caspases in sepsis |
| Q36009346 | Risk Models of Operative Morbidities in 16,930 Critically Ill Surgical Patients Based on a Japanese Nationwide Database |
| Q38890353 | Role of cellular events in the pathophysiology of sepsis |
| Q36412089 | Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis |
| Q46315054 | S1PR3 Signaling Drives Bacterial Killing and Is Required for Survival in Bacterial Sepsis. |
| Q95271890 | Sepsis Triggers a Late Expansion of Functionally Impaired Tissue-Vascular Inflammatory Monocytes During Clinical Recovery |
| Q59708886 | Sepsis and septic shock |
| Q38898328 | Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management. |
| Q38541110 | Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy |
| Q36430684 | Sepsis-induced immune dysfunction: can immune therapies reduce mortality? |
| Q38453261 | Sepsis: a roadmap for future research |
| Q96614801 | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts |
| Q26748401 | Sterile post-traumatic immunosuppression |
| Q36812451 | Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill: The Need for a Standardized Methodology |
| Q61797916 | Synergistic cytoprotection by co-treatment with dexamethasone and rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury |
| Q40567390 | Systemic Adenosine Triphosphate Impairs Neutrophil Chemotaxis and Host Defense in Sepsis. |
| Q91594800 | Systemic release of heat-shock protein 27 and 70 following severe trauma |
| Q55419461 | The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3. |
| Q61631793 | The Circadian Clock Controls Immune Checkpoint Pathway in Sepsis |
| Q47646317 | The Effect of Intraoperative N-Acetylcysteine on Hepatocellular Injury During Laparoscopic Bariatric Surgery. A Randomised Controlled Trial |
| Q27342598 | The Macrophage Mediates the Renoprotective Effects of Endotoxin Preconditioning |
| Q40046420 | The Role of S1PR3 in Protection from Bacterial Sepsis |
| Q26747005 | The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation |
| Q38280290 | The effect of HIV infection on the host response to bacterial sepsis |
| Q38991057 | The immune system's role in sepsis progression, resolution, and long-term outcome |
| Q52726992 | The systemic immune response to pediatric thermal injury. |
| Q92731362 | Thimet Oligopeptidase (EC 3.4.24.15) Key Functions Suggested by Knockout Mice Phenotype Characterization |
| Q27302768 | Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes |
| Q59792386 | Treatment duration with immune-based therapies in Cancer: an enigma |
| Q36291613 | Tuftsin-derived T-peptide prevents cellular immunosuppression and improves survival rate in septic mice |
| Q38510417 | Update in sepsis and acute kidney injury 2014. |
Search more.